Mouse models of lipodystrophy: Key reagents for the understanding of the metabolic syndrome

Drug Discovery Today: Disease Models

Volumn 4, Issue 1, 2007, Pages 17-24

  Asterholm, Ingrid Wernstedt ^a   Halberg, Nils ^a,b   Scherer, Philipp E ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; CYTOKINE; DIPHTHERIA TOXIN; HORMONE RECEPTOR STIMULATING AGENT; INDINAVIR; INSULIN RECEPTOR SUBSTRATE 1; INSULIN RECEPTOR SUBSTRATE 3; LEPTIN; LEUCINE ZIPPER PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PROTEINASE INHIBITOR; RITONAVIR; S6 KINASE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; BODY FAT DISTRIBUTION; DRUG TARGETING; FATTY LIVER; GENETIC MANIPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HYPERGLYCEMIA; HYPERINSULINEMIA; INSULIN RESISTANCE; KNOCKOUT MOUSE; LIPID LIVER LEVEL; LIPODYSTROPHY; METABOLIC DISORDER; METABOLIC SYNDROME X; NONHUMAN; OBESITY; PHENOTYPIC VARIATION; REVIEW; TISSUE SPECIFICITY;

EID: 37349063135     PISSN: 17406757     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddmod.2007.10.003     Document Type: Review

References (39)

1. Hegele R.A., et al. Thematic review series: adipocyte biology. Lipodystrophies: windows on adipose biology and metabolism. J. Lipid Res. 48 (2007) 1433-1444
2. Garg A. Adipose tissue dysfunction in obesity and lipodystrophy. Clin. Cornerstone 8 Suppl. 4 (2006) S7-S13
3. Ebihara K., et al. Efficacy and safety of leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy. J. Clin. Endocrinol. Metab. 92 (2007) 532-541
4. Javor E.D., et al. Long-term efficacy of leptin replacement in patients with generalized lipodystrophy. Diabetes 54 (2005) 1994-2002
5. Shimomura I., et al. Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue: model for congenital generalized lipodystrophy. Genes Dev. 12 (1998) 3182-3194
6. Asilmaz E., et al. Site and mechanism of leptin action in a rodent form of congenital lipodystrophy. J. Clin. Invest. 113 (2004) 414-424
7. Shimomura I., et al. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature 401 (1999) 73-76
8. Duan S.Z., et al. Hypotension, lipodystrophy, and insulin resistance in generalized PPARgamma-deficient mice rescued from embryonic lethality. J. Clin. Invest. 117 (2007) 812-822
9. Gavrilova O., et al. Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. J. Biol. Chem. 278 (2003) 34268-34276
10. Matsusue K., et al. Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes. J. Clin. Invest. 111 (2003) 737-747
11. He W., et al. Adipose-specific peroxisome proliferator-activated receptor gamma knockout causes insulin resistance in fat and liver but not in muscle. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 15712-15717
12. Jones J.R., et al. Deletion of PPARgamma in adipose tissues of mice protects against high fat diet-induced obesity and insulin resistance. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 6207-6212
13. Zhang J., et al. Selective disruption of PPARgamma 2 impairs the development of adipose tissue and insulin sensitivity. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 10703-10708
14. Koutnikova H., et al. Compensation by the muscle limits the metabolic consequences of lipodystrophy in PPAR gamma hypomorphic mice. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 14457-14462
15. Barroso I., et al. Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 402 (1999) 880-883
16. Tsai Y.S., et al. Hypertension and abnormal fat distribution but not insulin resistance in mice with P465L PPARgamma. J. Clin. Invest. 114 (2004) 240-249
17. Gray S.L., et al. Leptin deficiency unmasks the deleterious effects of impaired peroxisome proliferator-activated receptor gamma function (P465L PPARgamma) in mice. Diabetes 55 (2006) 2669-2677
18. Peterfy M., et al. Lipodystrophy in the fld mouse results from mutation of a new gene encoding a nuclear protein, lipin. Nat. Genet. 27 (2001) 121-124
19. Phan J., et al. Lipin expression preceding peroxisome proliferator-activated receptor-gamma is critical for adipogenesis in vivo and in vitro. J. Biol. Chem. 279 (2004) 29558-29564
20. Reue K., et al. Adipose tissue deficiency, glucose intolerance, and increased atherosclerosis result from mutation in the mouse fatty liver dystrophy (fld) gene. J. Lipid Res. 41 (2000) 1067-1076
21. Phan J., and Reue K. Lipin, a lipodystrophy and obesity gene. Cell Metab. 1 (2005) 73-83
22. Moitra J., et al. Life without white fat: a transgenic mouse. Genes Dev. 12 (1998) 3168-3181
23. Takemori K., et al. Elevated blood pressure in transgenic lipoatrophic mice and altered vascular function. Hypertension 49 (2007) 365-372
24. Gavrilova O., et al. Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice. J. Clin. Invest. 105 (2000) 271-278
25. Colombo C., et al. Transplantation of adipose tissue lacking leptin is unable to reverse the metabolic abnormalities associated with lipoatrophy. Diabetes 51 (2002) 2727-2733
26. Laustsen P.G., et al. Lipoatrophic diabetes in Irs1(-/-)/Irs3(-/-) double knockout mice. Genes Dev. 16 (2002) 3213-3222
27. Ross S.R., et al. Targeted expression of a toxin gene to adipose tissue: transgenic mice resistant to obesity. Genes Dev. 7 (1993) 1318-1324
28. Burant C.F., et al. Troglitazone action is independent of adipose tissue. J. Clin. Invest. 100 (1997) 2900-2908
29. El-Haschimi K., et al. Insulin resistance and lipodystrophy in mice lacking ribosomal S6 kinase 2. Diabetes 52 (2003) 1340-1346
30. Pajvani U.B., et al. Fat apoptosis through targeted activation of caspase 8: a new mouse model of inducible and reversible lipoatrophy. Nat. Med. 11 (2005) 797-803
31. Periard D., et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation 100 (1999) 700-705
32. Xu A., et al. Adiponectin ameliorates dyslipidemia induced by the human immunodeficiency virus protease inhibitor ritonavir in mice. Endocrinology 145 (2004) 487-494
33. Prot M., et al. Long-term treatment with lopinavir-ritonavir induces a reduction in peripheral adipose depots in mice. Antimicrob. Agents Chemother. 50 (2006) 3998-4004
34. Riddle T.M., et al. Leptin replacement therapy but not dietary polyunsaturated fatty acid alleviates HIV protease inhibitor-induced dyslipidemia and lipodystrophy in mice. J. Acquir. Immune Defic. Syndr. 33 (2003) 564-570
35. Riddle T.M., et al. HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory element-binding proteins in the nucleus. J. Biol. Chem. 276 (2001) 37514-37519
36. Hruz P.W., et al. Indinavir induces acute and reversible peripheral insulin resistance in rats. Diabetes 51 (2002) 937-942
37. Mulligan K., et al. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J. Acquir. Immune Defic. Syndr. 23 (2000) 35-43
38. Dube M.P., et al. Prospective, intensive study of metabolic changes associated with 48 weeks of amprenavir-based antiretroviral therapy. Clin. Infect. Dis. 35 (2002) 475-481
39. Murata H., et al. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J. Biol. Chem. 275 (2000) 20251-20254